Clinical Trial

A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort

Study acronym: ENDEAVOR
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Cohort 8 (non-ambulatory participants) is currently enrolling new participants. Enrollment for Cohorts 1 through 7 has been completed. This is an open-label gene transfer therapy study evaluating the safety of and expression from delandistrogene moxeparvovec in participants with Duchenne Muscular Dystrophy (DMD). The maximum participant duration for this study is 156 weeks.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2020-11-06; most recent amendment 2026-06-19.
Status change: Active, Not Recruiting → Recruiting 2025-12-19
Status change: Enrolling by Invitation → Active, Not Recruiting 2024-08-22
Status change: Recruiting → Enrolling by Invitation 2021-06-16
Status change: Not Yet Recruiting → Recruiting 2020-12-22
Trial Details
NCT Number NCT04626674
Lead Sponsor Sarepta Therapeutics, Inc.
Collaborators: Hoffmann-La Roche
Conditions Duchenne Muscular Dystrophy
Enrollment 83 participants
Start Date 2020-11-23
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2026-06-24